**Maine Society of Health-System Pharmacist**

**Fall Meeting**

**November 2, 2019**

**Pharmacist Handout**

**Impact of Clinician Burnout on Patient Safety: Journey to a Resilient & Thriving Healthcare Workforce**

**Paul W. Abramowitz, PharmD, Sc.D (Hon), FASHP, ASHP’s CEO**

*0837-9999-19-255-L05-P*

* Define burnout, well-being, and resilience
* Explain why clinician burnout is a patient care and healthcare workforce problem
* Discuss the U.S. National Academy of Medicine Clinician Well-Being and Resilience Action Collaborative
* Identify strategies to improve well-being and resilience in the healthcare workforce

**Vancomycin AUC: It’s Easy as 1,2,3**

**Brian McCullough, PharmD, BCPS**

*0837-9999-19-259-L01-P*

* Describe vancomycin’s pharmacodynamics activity
* Identify the current recommendations for vancomycin dosing
* Recognize the proper calculation for area under the curve

**Preventing Harm and Reducing Maine Overdose Deaths: A Naloxone and SUD Stigma Primer for Pharmacists**

**Stephaine Nichols, PharmD, BCPS, BCPP, FCCP**

**Kenneth McCall, BSPharm, PharmD, BCGP, FAPhA**

*0837-9999-19-261-L01-P*

* Recognize the impact of the opioid epidemic in Maine
* Identify stigmatizing terms related to patients with substance use disorder (SUD) and select appropriate alternatives
* Recognize the impact of stigmatizing terminology on patient care
* Recognize non-stigmatizing language to a scenario involving a patient with SUD
* Review SUD to other medical/psychiatric diseases and describe the harm reduction approach to care
* Describe the mechanism of naloxone and its place in therapy
* Identify persons at risk of an opioid overdose and signs of an overdose
* Summarize the characteristics of the various naloxone formulations including administration techniques
* Discuss critical patient education points regarding opioid overdose and naloxone

**Biosimilars: Current Trends and Future Directions**

**Christopher Peric, PharmD, BCPS**

*0837-9999-19-257-L01-P*

* Review biosimilar regulatory and development pathways
* Describe current formulary management approaches for biosimilars
* Discuss clinical and financial considerations for future biosimilar use

**Delegate Update on ASHP’s Summer Meeting**

**Kathryn Sawicki, PharmD**

**Matthew Christie, PharmD**

*0837-9999-19-264-L04-P*

* Review the policies presented for change at ASHP’s summer meeting
* Assess policies and changes that were extensively discussed
* Explain the use of policies in the national law making process
* Identify policies up for future discussion